Akeso’s candidate therapy cadonilimab, in combination with chemotherapy, showed encouraging results as a first-line treatment for advanced pancreatic cancer in the Phase 2 COMPASSION-26 study. The…
News
The European Commission has approved Ipsen’s oral therapy Ojemda (tovorafenib) to treat certain children with pediatric low-grade glioma (pLGG).
GYNECOLOGICAL CANCER
Mo-Rez shows strong early responses in ovarian, endometrial cancers
In an early clinical trial, people with certain advanced or treatment-resistant gynecological cancers showed strong responses to the experimental therapy mocertatug rezetecan (Mo-Rez), according…
The U.S. Food and Drug Administration (FDA) has granted fast track status to Opna Bio‘s OPN-6602 as a potential treatment for people…
AML World Awareness Day, an annual effort to educate people about acute myeloid leukemia (AML), is coming up on April 21, and the advocacy…
PANCREATIC CANCER
Daraxonrasib may offer new hope in previously treated pancreatic cancer
Most people with previously-treated metastatic pancreatic cancer lived for at least one year after receiving the oral therapy candidate daraxonrasib in a clinical trial…
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to plixorafenib as a potential treatment for adults with high-grade gliomas carrying…
GYNECOLOGICAL CANCER
New Keytruda regimen OK’d in EU for hard-to-treat gynecological cancers
A new regimen using the immunotherapy Keytruda (pembrolizumab) has been approved in the European Union for use by certain people with hard-to-treat gynecological…
The U.S. Food and Drug Administration (FDA) has agreed to review an application from Telix Pharmaceuticals seeking approval of TLX101-Px, the company’s experimental imaging…
The U.S. Food and Drug Administration (FDA) has given the green light for a first-in-human clinical trial to test a new cell therapy for acute…
Recent Posts
- Cadonilimab combo boosts survival in advanced pancreatic cancer patients
- A secondary diagnosis shows me how far I’ve come as a caregiver
- New targeted therapy Ojemda approved in EU for pediatric glioma
- Mo-Rez shows strong early responses in ovarian, endometrial cancers
- FDA grants fast track status to oral therapy for hard-to-treat myeloma
